health Democratic Republic of the Congo
Ebola prevention drug trial enrolls participants in eastern Congo
250participants
More than 250 participants have enrolled in the obeldesivir Ebola prevention trial.
A trial is testing Gilead’s experimental antiviral obeldesivir in people recently exposed to the Bundibugyo virus. The study is taking place in Ituri province during a major Ebola outbreak.
1 sourcePBS NewsUpdated
Claims
Support what holds up. Dispute what doesn't.
- 250participants
More than 250 participants have enrolled in the obeldesivir Ebola prevention trial.
“More than 250 participants have been enrolled in a trial for a drug that could stop them from contracting Ebola in Congo”
The trial is testing obeldesivir as post-exposure prophylaxis after suspected contact with the virus.
“The trial is testing Gilead's experimental antiviral pill, called obeldesivir, which is given soon after suspected contact with the virus to prevent the disease from developing.”
- 8,300confirmed cases
The outbreak has recorded at least 8,300 confirmed Ebola cases.
“At least 8,300 confirmed cases, including 4,000 deaths, have been recorded”